A Phase 2 interventional study of Rabeprazole 20 mg in Gastroesophageal Reflux Disease, sponsored by Eisai Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2013-05-20.
Sponsored by Eisai Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies testing rabeprazole in Gastroesophageal Reflux — none open to participants now, none under way, none of them phase 3. Rabeprazole · Gastroesophageal Reflux.
Among the 40 studies testing rabeprazole in Gastroesophageal Reflux, this one is the 13th largest by enrollment of the 39 interventional ones that give a count, is one of 5 that started in 2004, is one of 4 in phase 2, and was the 5th registered.
1,215 studies on the registry are indexed under Gastroesophageal Reflux; 203 are open to participants now.
Browse Gastroesophageal Reflux studies →None of the 40 studies testing rabeprazole in Gastroesophageal Reflux is open now. The open studies under Gastroesophageal Reflux, anywhere →
Rabeprazole: first FDA approval 1999 (ACIPHEX). What it is approved for, and how studies give it, is on its page →
Of the 133 Gastroesophageal Reflux studies recruiting now, 57 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 5 · Phase 3 17 · Phase 4 8
First in 2001; this study’s year is marked. 5 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 200 is above the median of 68 across 799 interventional studies indexed under Gastroesophageal Reflux.
Median enrollment 100 across the 39 interventional studies. Of the 38 that completed or were terminated, 15 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 40 have an industry lead sponsor. The 10 most frequent:
This study is registered under Eisai Inc., one of the names counted as Eisai Co., Ltd.. Under that name alone:
Eisai Inc. is the lead sponsor of 368 studies on the registry; 7 are open to participants now.
Of its 83 completed or terminated interventional studies of FDA-regulated products, 56 (67%) have results posted.
13 studies in Gastroesophageal Reflux by Eisai Co., Ltd.: none open now, none under way, none of them phase 3. Of 13 finished, 12 (92%) have results posted.
Among the 13 studies in Gastroesophageal Reflux by Eisai Co., Ltd., this one is the 10th largest by enrollment, is one of 2 that started in 2004, is one of 2 in phase 2, and was the 4th registered.
Eisai Co., Ltd.’s Gastroesophageal Reflux studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 40 studies testing rabeprazole in Gastroesophageal Reflux, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eisai Co., Ltd.’s 13 in Gastroesophageal Reflux:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study to determine the efficacy of 20 mg of rabeprazole given as a maintenance intermittent therapy following acute treatment for Symptomatic Gastroesophageal Reflux Disease (s-GERD).
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Rabeprazole 20 mg
Drug: Rabeprazole 20 mg
rabeprazole sodium tablet 20 mg once daily
Also known as: rabeprazole
The Percentage of Heartburn-free Days (24-hour Periods) During the 6-month Maintenance Treatment Phase (ITT Population).
The percentage of heartburn-free days during the 6-month Maintenance Treatment Phase in patients treated with rabeprazole 20 mg compared to patients who received placebo in the ITT Population. Heartburn-free day was defined as no heartburn in both the daytime and nighttime period on a given day. Note a total 388 subjects were enrolled at the beginning of Acute Phase and 200 subjects were enrolled into the double-blind 6-month maintenance treatment phase.
Time frame: 6 months double-blind maintenance phase
The Percent of Heartburn-free Daytime Period During the 6-month Maintenance Treatment Phase
The percentage of heartburn-free daytime period is presented cumulatively including all data collected during the 6-month Maintenance Phase
Time frame: 6-month maintenance phase
The Percent of Heartburn-free Nighttime Period During the 6-month Maintenance Treatment Phase
The percentage of heartburn-free nighttime period is presented cumulatively including all data collected during the 6-month
Time frame: 6-month maintenance phase
This study was recruited at 47 centers in the US during the period of 7-Oct-2004 and 12-Dec-2005.
| Milestone | Rabeprazole 20 mg | Placebo |
|---|---|---|
| Started | 103 | 97 |
| Completed | 73 | 35 |
| Not completed | 30 | 62 |
| Withdrew: Adverse event | 2 | 3 |
| Withdrew: Lack of efficacy | 6 | 33 |
| Withdrew: Lost to follow-up | 4 | 4 |
| Withdrew: Withdrawal by subject | 7 | 8 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Protocol violation | 6 | 8 |
| Withdrew: Other | 3 | 5 |
| Withdrew: Medication noncompliance | 1 | 1 |
The percentage of heartburn-free days during the 6-month Maintenance Treatment Phase in patients treated with rabeprazole 20 mg compared to patients who received placebo in the ITT Population. Heartburn-free day was defined as no heartburn in both the daytime and nighttime period on a given day. Note a total 388 subjects were enrolled at the beginning of Acute Phase and 200 subjects were enrolled into the double-blind 6-month maintenance treatment phase.
| Percentage of Days | Rabeprazole 20 mg | Placebo |
|---|---|---|
| The Percentage of Heartburn-free Days (24-hour Periods) During the 6-month Maintenance Treatment Phase (ITT Population). | 82.58 ± 14.39 | 62.17 ± 29.93 |
The percentage of heartburn-free daytime period is presented cumulatively including all data collected during the 6-month Maintenance Phase
Results for this outcome have not been posted.
The percentage of heartburn-free nighttime period is presented cumulatively including all data collected during the 6-month
Results for this outcome have not been posted.
Collected over 6 month maintenance phase. Non-serious events are listed at a 4% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rabeprazole 20 mg | — | — | — |
| Placebo | — | — | — |
| Event | Rabeprazole 20 mg | Placebo |
|---|---|---|
| Gallstone pancreatitisGastrointestinal disorders | 0/103 | 1/97 |
| PneumoniaInfections and infestations | 0/103 | 1/97 |
| Chest painGeneral disorders | 1/103 | 0/97 |
| Schizoaffective disorder/depressionNervous system disorders | 1/103 | 0/97 |
| Event | Rabeprazole 20 mg | Placebo |
|---|---|---|
| DiarrheaGastrointestinal disorders | 7/103 | 1/97 |
| Esophageal erosionGastrointestinal disorders | 2/103 | 6/97 |
| Hiatus herniaGastrointestinal disorders | 6/103 | 4/97 |
| EsophagitisGastrointestinal disorders | 4/103 | 5/97 |
| NauseaGastrointestinal disorders | 5/103 | 3/97 |
| HeadacheNervous system disorders | 5/103 | 3/97 |
| CoughRespiratory, thoracic and mediastinal disorders | 5/103 | 2/97 |
| Erosive gastritisGastrointestinal disorders | 2/103 | 4/97 |
| Viral gastroenteritisInfections and infestations | 0/103 | 4/97 |
| SinusitisInfections and infestations | 2/103 | 4/97 |
| Age Continuous(years) | Rabeprazole 20 mg | Placebo | Total |
|---|---|---|---|
| Mean | 46.0 ± 11.67 | 46.6 ± 11.69 | 46.3 ± 11.66 |
| Sex: Female, Male(Participants) | Rabeprazole 20 mg | Placebo | Total |
|---|---|---|---|
| Female | 64 | 59 | 123 |
| Male | 32 | 32 | 64 |
| Race (NIH/OMB)(Participants) | Rabeprazole 20 mg | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 9 | 10 | 19 |
| White | 74 | 64 | 138 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 12 | 16 | 28 |
The record gives a start of Oct 2004, a primary completion of Dec 2005 and a completion of Jun 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2009, 4 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rabeprazole